FTO
FTO is an RNA m6A demethylase that regulates energy homeostasis and adipogenesis by controlling the stability and translation of key metabolic mRNAs. Its intronic variants represent the strongest common genetic determinants of body mass index and obesity risk identified in GWAS studies.
Key Takeaways
- •FTO is the strongest known genetic risk locus for obesity, but the mechanism is surprisingly complex.
- •Its core function is an "eraser": it removes m6A methyl marks from RNA, changing mRNA stability and translation.
- •Many "FTO SNPs" actually act as a broken switch for neighboring genes (IRX3/5), preventing fat burning.
- •Exercise is highly effective at overriding FTO genetic risk, counteracting the metabolic penalties of the variants.
Basic Information
- Gene Symbol
- FTO
- Full Name
- Fat Mass and Obesity-Associated Protein
- Also Known As
- Hi95G6Alpha-ketoglutarate-dependent dioxygenase FTO
- Location
- 16q12.2
- Protein Type
- m6A RNA Demethylase ("Eraser")
- Protein Family
- AlkB family of dioxygenases
Related Isoforms
Key SNPs
The most studied obesity SNP. The risk (A) allele increases BMI and fat mass by impairing satiety cues in the brain.
Contains an enhancer that switches adipocytes from energy-burning (brown) to energy-storing (white) fat.
Highly correlated with rs9939609; robustly associated with increased caloric intake and preference for high-fat diets.
Consistently associated with adiposity across multiple ethnic groups; linked to altered metabolic rate.
Overview
FTO (Fat mass and obesity-associated protein) is a famous paradox in human genetics. It was originally discovered through genome-wide association studies (GWAS) as the single most powerful genetic contributor to human obesity. However, figuring out how it caused obesity took nearly a decade and revealed two entirely separate, fascinating biological mechanisms.
Mechanism 1 involves the FTO protein itself, which acts as an "RNA Eraser." It removes methyl marks (m6A) from messenger RNA (mRNA), controlling whether transcripts are translated, stored, or degraded. Mechanism 2 involves the famous "FTO SNPs" which sit in the gene's introns. These don't change the FTO protein but instead act as a broken enhancer that turns on distant genes (IRX3 and IRX5), locking fat cells into storage mode and preventing them from burning energy as heat.
Conceptual Model
A simplified mental model for the pathway:
If FTO erases a tag on an oncogene, the oncogene transcript survives and drives cancer. If it erases a tag on a hunger hormone receptor, satiety signaling changes.
Core Health Impacts
- • Body Composition: Major driver of polygenic obesity; risk alleles shift adipocytes from burning to storing.
- • Appetite Regulation: Modulates hunger and satiety in the hypothalamus, directly influencing food reward.
- • Oncology: Pathologically overexpressed in leukemias and solid tumors where it promotes cancer cell survival.
- • Neurogenesis: Regulates brain volume and adult neurogenesis; disruption linked to depression and Alzheimer’s.
Protein Domains
AlkB Dioxygenase Domain
The catalytic core. Uses Iron and Alpha-Ketoglutarate to perform oxidative demethylation of m6A residues.
C-Terminal Domain
Wraps around the catalytic core to stabilize it and dictate the enzyme’s specific preference for long mRNA substrates.
Upstream Regulators
Nutrient Excess Activator
High-fat diets and excess caloric intake upregulate FTO expression in the hypothalamus, driving further overeating.
Amino Acids Activator
FTO acts as an amino acid sensor; abundant essential amino acids directly enhance FTO activity to stimulate growth.
C/EBPα Activator
A transcription factor involved in adipogenesis that directly drives FTO gene transcription during fat cell differentiation.
Hypoxia Activator
Low oxygen conditions can induce FTO expression via HIF-1α in certain cancer contexts, aiding in tumor survival.
Downstream Targets
m6A-modified mRNAs Inhibits
The primary substrates. FTO removes m6A methyl marks, altering mRNA stability, splicing, and translation efficiency.
IRX3 and IRX5 Activates
FTO risk SNPs increase the expression of these distant genes, which prevent fat cells from browning/burning energy.
mTORC1 Activates
FTO promotes mTORC1 activity by demethylating transcripts of pathway inhibitors, leading to their degradation.
Ghrelin / Leptin Modulates
In the brain, FTO modulates satiety signaling, lowering sensitivity to leptin and increasing the ghrelin response.
Role in Aging
FTO’s role in aging is intimately tied to "Epitranscriptomics" (RNA epigenetics). The balance of m6A writing and erasing controls how quickly tissues can respond to stress and regenerate. FTO overactivity promotes aging phenotypes by driving excessive mTORC1 and impairing stem cell renewal.
Stem Cell Exhaustion
m6A marks are crucial for stem cells to differentiate. FTO overactivity erases these marks, stalling differentiation and leading to tissue degeneration.
Metabolic Aging
FTO variants accelerate age-related metabolic decline (visceral fat gain, insulin resistance) by suppressing fat burning via the IRX3/5 axis.
Neurogenesis
In the aging brain, proper m6A tagging is required for memory. Dysregulated FTO impairs learning and neurogenesis in older age.
Disorders & Diseases
Polygenic Obesity
Carriers of two risk alleles weigh on average 3kg more than non-carriers and have a 1.7-fold increased risk of severe obesity.
Acute Myeloid Leukemia (AML)
FTO is an oncogene in certain AML subtypes; it removes m6A from tumor suppressor transcripts, preventing cancer cell death.
Type 2 Diabetes
Strongly correlates with T2D risk, primarily secondary to increased BMI, but also via direct effects on pancreatic beta-cells.
Alzheimer’s & Brain Atrophy
FTO risk alleles are associated with reduced brain volume in the frontal lobes, predisposing to age-related cognitive decline.
Interventions
Supplements
A natural anthraquinone found in rhubarb that acts as a competitive inhibitor of FTO, increasing cellular m6A levels.
Shown to downregulate FTO expression and promote adipocyte browning (fat burning).
Polyphenol that may inhibit FTO expression and counteract adipogenic signaling from high-fat diets.
Supports the broader methylation cycle, helping to balance FTO "eraser" activity with m6A "writing."
Lifestyle
Highly effective at mitigating genetic risk; regular activity reduces the BMI penalty of FTO risk alleles by ~30%.
Decreases FTO expression in the hypothalamus and fat tissue, restoring m6A balance and improving satiety.
Helps overcome the impaired satiety cues caused by FTO variants, preventing the passive overeating common in risk carriers.
Medicines
An FDA-approved NSAID discovered to act as a selective inhibitor of FTO demethylase activity.
Experimental small-molecule inhibitors of FTO that suppress the proliferation of acute myeloid leukemia cells.
An oncometabolite that broadly inhibits dioxygenases, including FTO; used in research context.
Lab Tests & Biomarkers
Genetic Testing
A standard marker on commercial DNA tests to indicate genetic propensity for weight gain.
Activity Markers
A research assay measuring total m6A; low global m6A often implies pathologically high FTO activity.
Metabolic Output
Clinical proxy for fat tissue dysfunction; FTO risk alleles correlate with higher leptin and lower adiponectin.
Hormonal Interactions
Ghrelin Synergist
FTO variants are associated with impaired post-meal suppression of ghrelin, leading to rapid return of hunger.
Leptin Antagonist
Overexpression of FTO in the brain causes leptin resistance, blocking the "fullness" signal from fat stores.
Insulin Synergist
Hyperinsulinemia drives FTO expression in adipose tissue, reinforcing fat storage and blocking fat breakdown.
Cortisol Synergist
Chronic stress can upregulate FTO, linking stress-induced eating to epigenetic changes in the brain.
Deep Dive
Network Diagrams
The FTO-IRX3/5 Enhancer Circuit
FTO m6A Demethylation Reaction
Mechanism: The FTO “Broken Light Switch” Paradox
For years, scientists assumed the famous FTO SNPs (like rs1421085) caused obesity by mutating the FTO protein itself. In 2014-2015, groundbreaking research proved that these variants are actually in a “junk DNA” region (an intron) that forms a long-range enhancer loop.
This enhancer acts as a switch. In the “lean” genotype, a repressor protein (ARID5B) binds to the switch, turning OFF two distant genes: IRX3 and IRX5. When these are off, fat cells are free to become “brown” (thermogenic), burning fat to create heat. In the “obesity” genotype, a single letter change breaks the binding site. The repressor cannot attach, IRX3 and IRX5 get stuck “ON,” and fat cells are permanently locked into “white” (storage) mode.
FTO as an Epitranscriptomic Eraser
Completely independent of the enhancer mechanism, the FTO protein plays a monumental role in biology by erasing m6A marks from mRNA. To do this, FTO requires specific fuel: Oxygen, Iron, and a mitochondrial metabolite called Alpha-Ketoglutarate (α-KG).
When FTO erases an m6A mark, it changes the fate of the mRNA. For example, if an mRNA codes for a protein that turns off mTORC1, an m6A mark might flag it for rapid translation. If FTO erases that mark, the mRNA may be degraded instead, the repressor is never made, and mTORC1 stays hyperactive. This is how high FTO activity can drive cell growth, adipogenesis, and cancer progression.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark GWAS paper that identified FTO as the strongest genetic risk locus for polygenic obesity in humans.
Discovered the biochemical function of FTO as an m6A RNA demethylase, bridging metabolism and RNA epigenetics.
Revealed that FTO obesity SNPs exert metabolic effects primarily by altering the distant IRX3 gene, not FTO itself.
Mechanistically proved how the FTO rs1421085 variant disrupts an enhancer, switching fat cells from burning to storing.
Established FTO as a potent oncogene in leukemias, showing it erases m6A from transcripts to prevent cancer cell death.